Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Phase 4TerminatedNCT00566761

Asociación para Evitar la Ceguera en México10 enrolled

Overview

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Macular Edema Central Retinal Vein Occlusion

Interventions

bevacizumab and triamcinoloneDRUG

three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Macular edema secondary to central retinal vein occlusion * BCVA worse than 20/40 * Central macular \>250 mc with OCT Exclusion Criteria: * Diabetic retinopathy or other retinopathy * Media opacity that does not allow following * steroid responder * diagnosed glaucoma or IOP \> 21 mmHg

Locations (1)

Asociacion Para Evitar la Ceguera en Mexico

Mexico City, Coyoacan, Mexico

Outcomes

Primary Outcomes

Changes in Best corrected visual acuity and macular edema measured with OCT

Time frame: Follow up to 3 , 6 and 12 months

Secondary Outcomes

Report treatment complications

Time frame: 12 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.